Halseth Amy E, Ensor Nancy J, White Tommi A, Ross Stuart A, Gulve Eric A
Cardiovascular and Metabolic Diseases, Mail Zone T1G, 800 N. Lindbergh Boulevard, Pharmacia Corporation, St. Louis, MO 63167, USA.
Biochem Biophys Res Commun. 2002 Jun 21;294(4):798-805. doi: 10.1016/S0006-291X(02)00557-0.
The enzyme 5'AMP-activated protein kinase (AMPK) is activated by increases in intracellular AMP concentration through a complex interaction of phosphorylation and allosteric regulation. Actions of AMPK elucidated thus far suggest that AMPK may be a viable target for pharmacologic intervention in type II diabetes. Activation of AMPK is believed to mediate both the acute increase in skeletal muscle glucose uptake during exercise, as well as the adaptive responses to chronic exercise such as regulation of expression of components of the muscle glucose uptake system. In addition, AMPK is known to inhibit key enzymes involved in lipid and cholesterol synthesis, suggesting that activation of this kinase may also ameliorate dyslipidemia. To investigate the effects of AMPK activation in animal models of type II diabetes, db/db and ob/ob mice were administered 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR) subcutaneously either acutely (single injection) or twice per day for 8 days (chronic treatment). Blood glucose was lowered transiently in both db/db and ob/ob mice by acute AICAR treatment, returning to basal levels approximately 3 h after AICAR administration. In response to chronic treatment, blood glucose (measured 18 h post-AICAR administration) was significantly decreased in both mouse models when compared to vehicle control groups, with morning blood glucose values on Day 8 being decreased approximately 30-35% in both mouse models. Chronic AICAR administration also resulted in an elevation of total Glut4 concentration in skeletal muscle from ob/ob mice, but not db/db mice. In contrast to the beneficial effects on glucose metabolism, AICAR treatment of db/db and ob/ob mice led to approximately a 2.5-3-fold increase in serum triglyceride levels compared to vehicle-treated controls. These data suggest that pharmacological activation of AMPK may enhance glucose uptake in individuals with type II diabetes, however, this benefit may be offset by the concomitant elevation in triglycerides.
5'-腺苷酸激活蛋白激酶(AMPK)通过磷酸化和变构调节的复杂相互作用,被细胞内AMP浓度的增加所激活。迄今为止所阐明的AMPK的作用表明,AMPK可能是II型糖尿病药物干预的一个可行靶点。AMPK的激活被认为介导了运动期间骨骼肌葡萄糖摄取的急性增加,以及对慢性运动的适应性反应,如调节肌肉葡萄糖摄取系统成分的表达。此外,已知AMPK会抑制参与脂质和胆固醇合成的关键酶,这表明该激酶的激活也可能改善血脂异常。为了研究AMPK激活在II型糖尿病动物模型中的作用,给db/db和ob/ob小鼠皮下注射5-氨基咪唑-4-甲酰胺-1-β-D-呋喃核糖苷(AICAR),分为急性给药(单次注射)或每天两次,持续8天(慢性治疗)。急性AICAR治疗使db/db和ob/ob小鼠的血糖短暂降低,在AICAR给药后约3小时恢复到基础水平。在慢性治疗后,与载体对照组相比,两种小鼠模型的血糖(在AICAR给药后18小时测量)均显著降低,在第8天,两种小鼠模型的早晨血糖值均降低了约30 - 35%。慢性AICAR给药还导致ob/ob小鼠骨骼肌中总Glut4浓度升高,但db/db小鼠未出现这种情况。与对葡萄糖代谢的有益作用相反,与载体处理的对照组相比,AICAR处理的db/db和ob/ob小鼠血清甘油三酯水平升高了约2.5 - 3倍。这些数据表明,AMPK的药理学激活可能增强II型糖尿病患者的葡萄糖摄取,然而,这种益处可能会被甘油三酯的同时升高所抵消。